Journal
MATURITAS
Volume 73, Issue 4, Pages 275-279Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2012.08.009
Keywords
Breast cancer; Bone health; Osteoporosis
Categories
Funding
- Novartis
- Amgen
- NIH
- NIDCR [5K23DE020197-04]
Ask authors/readers for more resources
Breast cancer is a common diagnosis and the majority of women treated will be cured. Women with early stage breast cancer may be at increased risk for osteoporosis due to anticancer therapies. Chemotherapy induced amenorrhea and the use of anti-estrogens can promote bone loss: thus, the management of bone health in women with breast cancer is an important component of survivorship care. Osteoporosis is considered a silent disease as there are often no discrete warning signs, until a fracture occurs; therefore, clinicians must be cognizant of the underlying risk for osteoporosis and co-morbid conditions and/or medications that accelerate risk of fracture. Breast cancer therapies that effect bone, screening for bone loss and interventions to mitigate the treatment toxicities are reviewed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available